Showing 57481-57490 of 63593 results
- DocumentAccess to Essential Medicines Campaign, MSF, 1999Full text of the original 1977 Bangui Agreement which established the African Organization for Intellectual Property (OAPI) and the 1999 revisions which brought the agreement in line with TRIPS.(In French)DocumentGRAIN, 2001Examines the international protection of new varieties of plants, and outlines the difficulties developing countries in general, and African countries in particular, might encounter in the course of implementing these Conventions.The issues are examined for: UPOV Convention (1978 and 1991 Acts) TRIPSplant variety protection recommendations and the Convention on Biological DiveDocumentAccess to Essential Medicines Campaign, MSF, 2000This paper summarises the measures included in the original 1977 Bangui Agreement, which established the African Organization for Intellectual Property (OAPI) and regulates patents and IP in 15 west African states. It goes on to discuss the revised agreement which brought IP regulation in that region into line with the WTO TRIPS Agreement.DocumentBritish Medical Journal, 2002Short review of statistics, impacts and intervention startegies.Document
The evidence base for interventions in the care and management of AIDS in Low and Middle Income countriesCommission on Macroeconomics and Health, WHO, 2001Describes the clinical stages of HIV/AIDS, the scope of the problem of care, potential interventions and evidence of their effectiveness and cost-effectiveness, and constraints to scaling up the effective interventions.DocumentBritish Medical Journal, 2002Reviews the evidence for the economic impacts of AIDS in Africa and considers how economic theory can contribute to an effective response to the pandemic.Argues that: Economic research helps to estimate the effects of HIV/AIDS on the African economy and the cost effectiveness of prevention and treatment programmesEconomic theory predicts that HIV/AIDS reduces labour supply and prodDocumentBritish Medical Journal, 2002Short paper argues that an effective, affordable, and accessible HIV vaccine is within reach . Equitable public-private partnerships between researchers, manufacturers, and distributors and partnerships between rich and poor countries are the best strategy for the development of the vaccine.DocumentBritish Medical Journal, 2002The first trial of a candidate HIV-1 vaccine in Africa was completed in Uganda in 2001. It involved a randomised, placebo controlled trial of a vaccine in healthy volunteers at low risk of HIV infection.DocumentCommission on Macroeconomics and Health, WHO, 2001The Heavily Indebted Poor Countries (HIPC) Debt Initiative is the first international effort to reduce the external debt of the world’s poorest, most heavily indebted countries, and represents an important step forward in placing debt relief within an overall framework of poverty reduction.Document
The evidence base for interventions to reduce maternal and neonatal mortality in Low and Middle-Income countriesCommission on Macroeconomics and Health, WHO, 2001Reviews the scale of maternal and neonatal mortality and serious morbidity in low and middle income countries, and the factors that account for the huge discrepancies in the rates of these poor outcomes compared with high income countries.